These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Monoclonal antibody therapy for solid tumors. Green MC; Murray JL; Hortobagyi GN Cancer Treat Rev; 2000 Aug; 26(4):269-86. PubMed ID: 10913382 [TBL] [Abstract][Full Text] [Related]
5. Sixth biannual report of the Cochrane Haematological Malignancies Group--focus on non-Hodgkin lymphoma. Weingart O; Rehan FA; Schulz H; Naumann F; Knauel I; Bohlius CB; Engert A J Natl Cancer Inst; 2007 Sep; 99(17):E1. PubMed ID: 17728205 [No Abstract] [Full Text] [Related]
6. Interleukin-2 and lymphokine-activated killer cell therapy in patients with relapsed B-cell lymphoma treated with rituximab. Pitini V; Arrigo C; Naro C; Altavilla G Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5497. PubMed ID: 17875780 [No Abstract] [Full Text] [Related]
7. Rituximab in diffuse large B-cell lymphoma. Coiffier B Clin Adv Hematol Oncol; 2004 Mar; 2(3):156-7. PubMed ID: 16166943 [No Abstract] [Full Text] [Related]
8. Monoclonal antibodies: potential applications to the treatment of cancer. Houghton AN; Scheinberg DA Semin Oncol; 1986 Jun; 13(2):165-79. PubMed ID: 3520825 [No Abstract] [Full Text] [Related]
9. [Treatment of B cell lymphoma by using monoclonal antibodies]. Tobinai K Nihon Naika Gakkai Zasshi; 2001 Jun; 90(6):1106-11. PubMed ID: 11460379 [No Abstract] [Full Text] [Related]
10. A new generation of monoclonal antibodies arrives at the clinic. McNeil C J Natl Cancer Inst; 1995 Nov; 87(22):1658-60. PubMed ID: 7473810 [No Abstract] [Full Text] [Related]
11. Biologic response modifiers as adjuncts to other therapeutic modalities. Borden EC; Hawkins MJ Semin Oncol; 1986 Jun; 13(2):144-52. PubMed ID: 2424086 [No Abstract] [Full Text] [Related]
12. Monoclonal antibody 791T/36 for tumor detection and therapy for metastases. Baldwin RW; Pimm MV; Embleton MJ; Armitage NM; Farrands PA; Hardcastle JD; Perkins A Symp Fundam Cancer Res; 1983; 36():437-55. PubMed ID: 6382519 [No Abstract] [Full Text] [Related]
13. Potential clinical utility of monoclonal antibodies in the management of human carcinomas. Schlom J; Weeks MO Important Adv Oncol; 1985; ():170-92. PubMed ID: 3916739 [No Abstract] [Full Text] [Related]
14. Monoclonal antibodies for medical oncology: a few critical perspectives. Belda-Iniesta C; Ibáñez de Cáceres I; de Castro J Clin Transl Oncol; 2011 Feb; 13(2):84-7. PubMed ID: 21324795 [TBL] [Abstract][Full Text] [Related]
15. [New antibodies in cancer treatment]. Pestalozzi BC; Knuth A Praxis (Bern 1994); 2004 Sep; 93(39):1589-92. PubMed ID: 15500243 [TBL] [Abstract][Full Text] [Related]
16. Herceptin in early breast cancer: a call for judicious use. Thorat MA Natl Med J India; 2005; 18(6):315-7. PubMed ID: 16483033 [No Abstract] [Full Text] [Related]
17. The clinical use of antibodies in haematological malignancies. López-Guillermo A; Mercadal S Ann Oncol; 2007 Jul; 18 Suppl 9():ix51-7. PubMed ID: 17631596 [No Abstract] [Full Text] [Related]
18. Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with rituximab, a chimeric anti-CD20 monoclonal antibody. Soda R; Costanzo A; Cantonetti M; Orlandi A; Bianchi L; Chimenti S Acta Derm Venereol; 2001; 81(3):207-8. PubMed ID: 11558880 [No Abstract] [Full Text] [Related]
19. Trastuzumab for early breast cancer. Stuart NS; Bishop J; Bale C Lancet; 2006 Jan; 367(9505):107-8. PubMed ID: 16413865 [No Abstract] [Full Text] [Related]
20. New agents in colon cancer. Hurwitz HI Clin Adv Hematol Oncol; 2003 Jul; 1(7):404-5. PubMed ID: 16258421 [No Abstract] [Full Text] [Related] [Next] [New Search]